Navigation Links
Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
Date:10/26/2008

Iclaprim also achieved high eradication rates for the most common pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)

REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid. A New Drug Application for intravenous iclaprim in cSSSI will be discussed at the meeting of the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee on 20 November 2008.

Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) selective inhibitor class of antibiotics, was specifically designed to address the growing need for additional treatment options to combat resistant infections including MRSA. MRSA affects more than 2 million people in the United States each year and rates of hospital- and community-acquired MRSA are on the rise.(i,ii)

"The high efficacy rates and favorable tolerability profile of iclaprim strongly supports its potential as a new treatment option for patients who have acquired serious infections caused by MRSA," said Dennis L. Stevens, MD, PhD, Veterans Affairs Medical Center, Boise, Idaho. "With rates of MRSA increasing and effectiveness of some current antibiotics declining, it is important to identify effective alternative treatments for these infections."

The results presented at the ICAA
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 The Assistance Fund ... This program provides financial assistance for copay to individuals ... to announce the addition of the Melanoma Copay Assistance ... Mark McGreevy , executive director. "With each additional program ... of a world where no one is denied access ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
(Date:5/22/2015)... May 22, 2015  The Mesothelioma Victims Center ... of mesothelioma get the best possible compensation, and they ... with this rare cancer caused by exposure to ... information related to treatment options such as a ... the Mesothelioma Victims Center anytime at 866-714-6466. ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... 5, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) ... commercializing small,molecule drugs to treat severe medical ... of overall survival (OS) time,for patients in ... clinical trial in metastatic melanoma for its,lead ...
... 5, 2007 - Gloucester,Pharmaceuticals, Inc., a privately held ... romidepsin as a,treatment for cutaneous T-cell lymphoma (CTCL) ... American Society of,Clinical Oncology (ASCO) Annual Meeting being ... of an interim analysis of a phase II,study ...
Cached Medicine Technology:Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 2Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 3Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 4Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 5Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 6Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 7Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 2Gloucester Pharmaceuticals Reports Positive Interim Phase II Data,on Romidepsin for T-Cell Lymphomas at the 2007 American Society of,Clinical Oncology Annual Meeting 3
(Date:5/22/2015)... 22, 2015 Pioneer Millworks, the largest ... forefront of designing with reclaimed wood, introducing their latest ... Angeles, California. Their newest offerings, Vat 35, Reclaimed ... and color to America's largest design event. , “Designers, ... each show, anxious to see and feel the variety ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 River Valley ... Kyle Johnson, the health system’s Chief Financial Officer (CFO), ... Johnson has served as the company CFO since 2011. ... will be joining the health system as CFO. Wesley ... interim basis, while the Board of Trustees conducts a ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
(Date:5/22/2015)... 22, 2015 Coordinating care for ... process. Historically providers have not been reimbursed or ... in 2015, Medicare has paved the way by ... to the launch of Oculus Health , ... systems using the platform will now be able ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
... By Alan Mozes HealthDay Reporter , THURSDAY, ... illness are being reported among college students than a decade ... a post-secondary education and are open to getting help when ... use of prescription medications by students to treat psychiatric illness ...
... European Urology , the official journal of the European Association ... the September issue: Case Series of the month. This series ... only preliminary results. The Case Series reports on no more ... Education question with multiple choice answers is also included to ...
... , WEDNESDAY, Aug. 11 (HealthDay News) -- A debilitating and usually ... transplant, a new study finds. , , The results may ... for the potential of stem cells in bone marrow to turn ... Aug. 12 issue of the New England Journal of Medicine ...
... nationwide research initiative has been launched to define changes in ... in response to infection or to vaccination. Six U. S.-based ... million over five years to conduct this research. ... of Allergy and Infectious Diseases (NIAID), part of the National ...
... least a quarter of patients who have suffered a stroke ... medications within the first three months after being hospitalized ... according to a new study by researchers at Wake Forest ... there are an estimated 180,000 recurrent strokes in the United ...
... Medicine,s Department of Public Health Sciences has received a ... act as the data coordinating center for the National ... one of the largest in the college,s history. AsthmaNet ... the nation that conducts clinical trials to address new ...
Cached Medicine News:Health News:College Campuses See Rise in Cases of Severe Mental Illness 2Health News:College Campuses See Rise in Cases of Severe Mental Illness 3Health News:New case series section in European Urology 2Health News:Stem Cell Treatment May Offer Hope Against Fatal Skin Disorder 2Health News:Stem Cell Treatment May Offer Hope Against Fatal Skin Disorder 3Health News:NIH launches effort to define markers of human immune responses 2Health News:1 in 4 stroke patients stop taking prevention medication within 3 months 2Health News:1 in 4 stroke patients stop taking prevention medication within 3 months 3Health News:1 in 4 stroke patients stop taking prevention medication within 3 months 4Health News:College Of Medicine receives $54 million grant for asthma research 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: